Prof. Laure Gossec (Sorbonne Universite, Paris, France) kindly took the time to speak with touchIMMUNOLOGY about the long-term impact of the IgG1 inhibitor, bimekizumab, on patient-reported outcomes from the phase 2b BE ACTIVE study (NCT02969525) and its open-label extension (NCT03347110).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The poster entitled ‘Sustained Improvement in Physical Function, Disease Impact and HealthÂ-Related Quality of Life in Patients with Psoriatic Arthritis Treated with Bimekizumab: 3-Year Results from a Phase 2b Open-Label Extension Study’ (ABSTRACT NUMBER: 1350) was presented at the ACR Convergence, 5-9 November 2021.
Questions
- How important are patient-reported outcomes as a clinical endpoint in psoriatic arthritis (PsA)? (0:10)
- What were the aims of the current analysis of the BE ACTIVE and OLE study data? (0:51)
- What was the impact of bimekizumab on patient-reported outcomes? (1:28)
Disclosures: Prof. Laure Gossec has received grant/research support from ​Galapagos, Sandoz, Sanofi, Amgen, Eli Lilly, Janssen and Pfizer; and acted as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Biogen, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
